Nurix Therapeutics Inc. is a biopharmaceutical company focused on developing targeted protein modulation therapies for the treatment of cancer and other diseases. The company was founded in 2015 by Dr. Arthur Sands and is based in San Francisco, California. Nurix utilizes its proprietary protein modulation platform to discover and develop small molecule drugs that can selectively modulate the activity of specific proteins within the cell.
Nurix's innovative approach is based on the concept of ubiquitin-mediated protein degradation, a critical process for maintaining cellular homeostasis. The company's platform leverages the ubiquitin-proteasome system to selectively eliminate disease-causing proteins or activate disease-fighting proteins within cells. By modulating the activity of these proteins, Nurix aims to develop novel therapies with the potential to address unmet medical needs.
Nurix has a robust pipeline of potential drug candidates targeting various diseases, including cancer. The company's lead program focuses on the treatment of hematological malignancies and solid tumors by modulating the degradation of specific proteins involved in oncogenesis. Nurix's approach has the potential to offer more precise and effective treatments with fewer side effects compared to traditional therapies.